Solabia has acquired BioActor, a Dutch developer of natural active ingredients used by food supplement brands.
The French outfit said the investment will allow Solabia to benefit from a wider range of ingredients and from BioActor’s expertise as customers increasingly look for high quality actives that combine naturality with proof of efficacy.
Founded in 2011 and located on the Maastricht Health Campus, BioActor develops and commercialises clinically evaluated polyphenols extracted from edible plants and fruits.
BioActor currently exports to more than 20 countries worldwide, serving leading brands across the nutrition and supplement industries.
Solabia said the acquisition will also support BioActor’s continued focus on R&D and product development, as well as the expansion of its production capabilities, enabling the company to serve the increasing global demand for its products.
The Paris company is already present in the nutrition segment through original ingredients recognized for their health benefits, including Algatech’s microalgae-derived active ingredients.
“BioActor will become a centre of excellence for innovation and clinical research within Solabia’s nutrition division and the combination will allow both companies to benefit from the combined network and expertise, as well as to access new marketing channels and an expanded customer base,” a spokeswoman said.
Hans van der Saag, BioActor’s founder, retains a minority share and his role as CEO of BioActor.
“Together with Solabia, we are poised to extend the BioActor growth story as part of a larger organisation with an extensive global footprint, a shared commitment to innovation, research and development, and an unwavering focus on utilising the benefits of nutrition to elevate the health of all of us,” he said.
